Vaccinex, Inc. SIGNAL (VX15-2503-N-131) Cohort B Topline Results

September 22, 2020 @8:30 AM

Forward Looking Statement

To the extent that statements contained in this presentation are not descriptions of historical facts

regarding Vaccinex, Inc. ("Vaccinex," "we," "us," or "our"), they are forward-looking statements

reflecting management's current beliefs and expectations. Such statements include, but are not

limited to, statements about our plans, expectations and objectives with respect to the results and

timing of our Phase 2 SIGNAL trial of pepinemab (VX15/2503) in Huntington's disease and other

clinical trials, the use and potential benefits of pepinemab in Huntington's disease and other

indications, and other statements identified by words such as "may," "will," "appears," "expect,"

"anticipate," "estimate," "intend," "hypothesis," "potential," "advance," and similar expressions or

their negatives (as well as other words and expressions referencing future events, conditions, or

circumstances). Forward-looking statements involve substantial risks and uncertainties that could

cause the outcome of our research and pre-clinical development programs, clinical development

programs, future results, performance, or achievements to differ significantly from those expressed or

implied by the forward-looking statements. Such risks and uncertainties include, among others,

uncertainties inherent in the execution, cost and completion of preclinical and clinical trials,

uncertainties related to regulatory approval, risks related to our dependence on our lead product

candidate pepinemab, the impact of the COVID-19 pandemic, and other matters that could affect our

development plans or the commercial potential of our product candidates. Except as required by law,

we assume no obligation to update these forward-looking statements. For a further discussion of

these and other factors that could cause future results to differ materially from any forward-looking

statement, see the section titled "Risk Factors" in our periodic reports filed with the Securities and

Exchange Commission ("SEC") and the other risks and uncertainties described in our Form 10-K dated

2

March 9, 2020 and subsequent filings with the SEC.

One Touch Stockings (OTS) - Cohort B1 Co-Primary 1a: Cognitive Assessment

One-

Success

sided p-

Favors

[Critical

value

PEPI

value]

0.028

Yes

No

[0.025]

[0.0125]

Difference (PEPI - PBO)

Change from Baseline at Month 17 (95% CI) = -1.98(-4.00, 0.05)

3

OTS Assessment of Executive Function - Planning and Memory

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Vaccinex Inc. published this content on 22 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 September 2020 14:59:08 UTC